Given its ability to engage both T cell activation and potential ADCC via NK cells, combining cosibelimab with other ICIs, such as CTLA-4 inhibitors or newer agents targeting LAG-3 or TIGIT, could synergistically overcome resistance mechanisms and improve anti-tumor immune responses. The gene discussed is LAG3; the disease is neoplasm.